<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259255</url>
  </required_header>
  <id_info>
    <org_study_id>REFINE-ALS</org_study_id>
    <nct_id>NCT04259255</nct_id>
  </id_info>
  <brief_title>Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)</brief_title>
  <official_title>Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma America Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma America Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to
      identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone
      effects in ALS. Epigenetic and protein biomarkers will also be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be prescribed by HCPs in accordance with their clinical judgement and the
      prescribing information for Edaravone. The decision to prescribe Edaravone to the
      participants should be made separately from the decision to enroll then in the study. There
      will be no randomized assignments to treatment and no restrictions on the use of commercially
      available medications (but those participating in an experimental study, even if taking
      Edaravone, will be excluded). No experimental treatment is evaluated in this study. The
      intervention is limited to the collection of blood and urine samples for biomarker testing.

      During the estimated study period, eligible patients who are prescribed Edaravone within the
      approved indication will be invited to participate in the study. An initial
      screening/baseline visit will be scheduled for participants who are considered for study
      participation.

      Participants in this study will be followed from enrollment up to 24 weeks after treatment
      initiation (6 treatment cycles [each cycle consisting of 28 days], corresponding to a
      treatment period of approximately 24 weeks) or premature study discontinuation. Throughout
      the study period, the investigators will record participant baseline and follow-up
      information and perform clinical and biomarker assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in levels of 4-hydroxynoneal (4-HNE) as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for 4-HNE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in levels of 8-F2 isoprostanes as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for 8-F2 isoprostanes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of 3-nitrotyrosine (3-NT) as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for 3-NT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples 8-OHdG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of urate as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for urate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of matrix metalloproteinase-9 (MMP-9) as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for MMP-9.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of urinary neutrophin receptor p75 as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for urinary neutrophin receptor p75.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of neurofilaments (Nf) (Heavy and Light) as a potential biomarker of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for neurofilaments (Nf) (Heavy and Light).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of creatinine as a potential biomarkers of oxidative stress, inflammation or neurodegeneration.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Collection of blood and/or urine samples for creatinine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ALSFRS-R (ALS Functional Rating Scale .Revised) Score</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>The ALSFRS-R is a quickly administered ordinal rating scale (ratings 0-4) used to determine participants' assessment of their capability and independence in 12 functional activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the King's Clinical Staging.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>The King's clinical staging is based on the number of body regions affected by ALS and the presence of respiratory or nutritional failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ALSAQ-40 (ALS Assessment Questionnaire).</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>The ALSAQ-40 is a questionnaire that consists of 40 questions/items with 5 discrete scales: physical mobility, activities of daily living and independence, eating and drinking, communication, emotional reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Appel ALS Score.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>The Appel ALS score consists of five sub-scores: bulbar, respiratory, muscle strength, and lower extremity and upper extremity function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in slow vital capacity.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>The vital capacity (VC) (percent of predicted normal) will be determined, using the upright slow VC method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hand-held dynamometry.</measure>
    <time_frame>Cycles 1, 3, and 6 of each Edaravone cycle (each cycle is 28 days).</time_frame>
    <description>Hand-held dynamometry (HHD) will be used as a quantitative measure of muscle strength for this study.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Edaravone</arm_group_label>
    <description>During an estimated 12-month period, eligible participants who are prescribed Edaravone within the approved indication will be invited to participate in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <description>Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.
Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles.</description>
    <arm_group_label>Edaravone</arm_group_label>
    <other_name>Radicava®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted in participants who have sporadic or familial amyotrophic
        lateral sclerosis (ALS) as defined by revised El Escorial criteria. Participants must
        provide written informed consent prior to screening. At screening, eligible patient must be
        at least 18 years old with a decision made to prescribe Edaravone prior to consenting.
        Participants who are either Edaravone naïve or who did not receive any Edaravone dose
        within one month of consenting are eligible for inclusion given they meet all other
        protocol requirements.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female aged 18 years or older at enrollment

          -  Sporadic or familial ALS diagnosed as possible, probable, probable-laboratory
             supported or definite as defined by the World Federation of Neurology revised El
             Escorial criteria

          -  Decision made to prescribe Edaravone prior to screening

          -  Participant will likely be able to obtain commercial Edaravone and likely to complete
             6 cycles of treatment, per site investigator estimation

          -  Participant either naïve to Edaravone or who did not receive any Edaravone does within
             1 month prior to screening

          -  Signed informed consent by the subject, or a witness if a subject cannot read or write
             or is physically unable to talk or write, obtained before any study-related activities
             are undertaken

        Exclusion Criteria:

          -  Participant with a contraindication to Edaravone

          -  Participant is participating in an interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Berry, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massachusetts General Hospital</last_name>
    <phone>617-724-2609</phone>
    <email>Lmtamburello@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Massachusetts General Hospital</last_name>
    <phone>617-724-4246</phone>
    <email>mdavis52@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix VA Health Care System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Kuramoto</last_name>
      <email>MaryAnn.Migaud@va.gov</email>
    </contact>
    <investigator>
      <last_name>Mary Ann Migaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Turcotte</last_name>
      <email>nicole.turcotte@dignityhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Shaundra Hall</last_name>
      <email>Shaundra.Hall@DignityHealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristy Osgood</last_name>
      <email>nrcresearch@nrcaz.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Als Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Bercow</last_name>
      <email>JBercow@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA GLA ALS Multidisciplinary Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Hanssen</last_name>
      <email>Andrea.Hanssen@VA.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivian Li</last_name>
      <email>vcli1@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colleen Anthonisen</last_name>
      <email>canthonisen@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marguerite Engel</last_name>
      <email>engelm@cpmcri.org</email>
    </contact>
    <contact_backup>
      <last_name>Simon Carty</last_name>
      <email>cartys@sutterhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannah George</last_name>
      <email>hannah.george@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neurology Research Group at UC Denver</last_name>
      <email>NeurologyResearchPartners@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis Ahmad</last_name>
      <email>asc73@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville -Neurology Research Department</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alyssa Ruckel</last_name>
      <email>alyssa.ruckel@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Smith</last_name>
      <email>lisa.smith@jax.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Thuro</last_name>
      <email>Thuro.Lisa@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janay Caradonna</last_name>
      <email>caradonna.janay@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Schleutker</last_name>
      <email>allisonschle@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ben Joslin</last_name>
      <email>ben.joslin@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hellen Tanui</last_name>
      <email>htanui@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betty Mosmiller</last_name>
      <email>emosmil1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Lieberman</last_name>
      <email>clieberman1@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Douthwright</last_name>
      <email>Catherine.Douthwright@umassmed.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane McKenna-Yasek</last_name>
      <email>Diane.McKenna-Yasek@umassmed.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Vallis</last_name>
      <email>avallis1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute/Twin Cities ALS Consortium</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pyle</last_name>
      <email>maria.x.pyle@healthpartners.com</email>
    </contact>
    <contact_backup>
      <last_name>Emily Green</last_name>
      <email>Emily.A.Green@HealthPartners.Com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raghav Govindarajan, MD, FAAN</last_name>
      <email>govindarajanr@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Department of Neurology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Brown</last_name>
      <email>susan.a.brown@health.slu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Morefield</last_name>
      <email>christina.morefield@health.slu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Karanja</last_name>
      <email>ekaranja@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Jockel-Balsarotti</last_name>
      <email>jockelji@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley D Calhoun</last_name>
      <email>ashley@somnos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaitlyn Fell</last_name>
      <email>fell.k@lasvegasclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brixhilda Dedi</last_name>
      <email>bd2577@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health, Carolinas HealthCare System Neurosciences Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison Newell-Sturdivant</last_name>
      <email>allison.newell-sturdivant@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Hastings</last_name>
      <email>hastind@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OhioHealth</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Ferguson</last_name>
      <email>elizabeth.ferguson@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>John Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arlena Cummings</last_name>
      <email>arlena.cummings@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Lewis Katz School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol VonHofen</last_name>
      <email>carol.vonhofen@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Hatala</last_name>
      <email>kathleen.hatala@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Madden</last_name>
      <email>maddenka@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Applegate</last_name>
      <email>rgapplegate@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kittrell</last_name>
      <email>kittrellp@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Crystal Neate</last_name>
      <email>crystal.neate@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cardey</last_name>
      <email>jennifer.cardey@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sissons-Ross</last_name>
      <email>lsissons@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Mejaki</last_name>
      <email>mmejaki@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>edaravone</keyword>
  <keyword>Radicava®</keyword>
  <keyword>motor neuron disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

